Molnupiravir Outpatient Treatment for Adults with COVID-19 in a Real-World Setting—A Single Center Experience

Background: Molnupiravir is approved for the treatment of adult patients with mild to moderate COVID-19. The main goal of the treatment is to reduce hospitalization and mortality rate. This study aimed at the all-cause hospitalization and all-cause death assessment in patients at high risk of severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Czarnecka, Kinga, Czarnecka, Paulina, Tronina, Olga, Durlik, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656557/
https://www.ncbi.nlm.nih.gov/pubmed/36362691
http://dx.doi.org/10.3390/jcm11216464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656557/
https://www.ncbi.nlm.nih.gov/pubmed/36362691
http://dx.doi.org/10.3390/jcm11216464

Ejemplares similares